#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic inflammatory demyelinating polyradiculoneuropathy Kawasaki's disease Urea cycle disorder Chondrodystrophy Kaposi's sarcoma Choroidal dystrophy Propionic acidaemia Cortical dysplasia Idiopathic inflammatory myopathy Amyotrophic lateral sclerosis gene carrier Cystic fibrosis gastrointestinal disease Palmoplantar pustulosis Factor IX deficiency Hypereosinophilic syndrome Crohn's disease More trials…

    Learn about Rare Diseases

    Fragile X syndrome Mucopolysaccharidosis I – Life with Disease Gaucher’s disease type I – Trials in Disease Vascular malformation – Trials in Disease Ewing’s sarcoma recurrent – Trials in Disease Alport’s syndrome – Diagnostics Hereditary neuropathic amyloidosis – Trials in Disease Mantle cell lymphoma stage IV – Trials in Disease MELAS syndrome – Life with Disease Undifferentiated sarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Desloratadine Ly3541860 Neratinib ANOC-001 Tanimilast Ceritinib Albiglutide Clofazimine Donanemab Kyv-101 Sulfonamides, Urea Derivatives Moxifloxacin Hydrochloride Avalotcagene Ontaparvovec Abc-24F-116 Insulin Aspart Ganciclovir Sodium Ly3437943 Sodium Mcla-129 Buloxibutid IHMA-2121771-1 More therapies…

    Learn about Your Condition

    Diabetic retinal oedema Raynaud's phenomenon Malignant oligodendroglioma Noonan syndrome Dent's disease Lennox-Gastaut syndrome Metastasis Haemodialysis Oral neoplasm Influenza Psychological trauma Pulmonary embolism Guttate psoriasis Oropharyngeal cancer Left ventricular dysfunction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Metastatic gastric cancer
    • Oesophageal adenocarcinoma
    • Breast cancer
    Spain

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Human epidermal growth factor receptor negative
    • Breast cancer
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    France Germany Italy Spain

  • A Study of Disitamab Vedotin for Adults with HER2 Expressing Advanced Breast Cancer

    Recruiting

    1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Disitamab Vedotin
    Germany Italy Spain

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • RLY-2608
    • Capivasertib
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zanidatamab
    Spain

  • A Study of BNT323 and BNT327 for Patients with Advanced Breast Cancer to Test Safety and Effectiveness

    Recruiting

    1 1 1
    Investigated Drugs:
    • Db-1303
    • BNT327
    France Italy Spain
Previous Page
1 2 3 4 … 28
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!